June 4-8, 2021; Online at https://conferences.asco.org/am
Addition of isatuximab to carfilzomib/dexamethasone improved PFS in patients with difficult-to-treat R/R MM, including older patients, patients with MM refractory to previous therapy, and those with high-risk cytogenetics.